Chemistry:Vicasinabin
From HandWiki
Vicasinabin (RG7774) is a potent cannabinoid agonist which is highly selective for the CB2 receptor subtype. It was developed by Roche as a potential agent for the treatment of diabetic retinopathy. It reached Phase II human clinical trials but was discontinued for lack of efficacy, although it continues to be used for scientific research.[1][2]
References
- ↑ "RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models". Frontiers in Pharmacology 15. 2024. doi:10.3389/fphar.2024.1426446. PMID 39070793.
- ↑ "CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy". Ophthalmology Science 5 (2). 2025. doi:10.1016/j.xops.2024.100650. PMID 39802207.
 |  |
